Gradilone Sergio A, O'Hara Steven P, Masyuk Tetyana V, Pisarello Maria Jose Lorenzo, LaRusso Nicholas F
Division of Gastroenterology and Hepatology, and the Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic, Rochester, Minnesota.
Semin Liver Dis. 2015 Feb;35(1):26-35. doi: 10.1055/s-0034-1397346. Epub 2015 Jan 29.
Cholangiocytes, the epithelial cells lining the biliary tree, represent only a small portion of the total liver cell population (3-5%), but they are responsible for the secretion of up to 40% of total daily bile volume. In addition, cholangiocytes are the target of a diverse group of liver diseases affecting the biliary tract, the cholangiopathies; for most of these conditions, the pathological mechanisms are unclear. MicroRNAs (miRNAs) are small, noncoding RNAs that posttranscriptionally regulate gene expression. Thus, it is not surprising that altered miRNA profiles underlie the dysregulation of several proteins involved in the pathobiology of the cholangiopathies, as well as showing promise as diagnostic and prognostic tools. Here the authors review recent work relevant to the role of miRNAs in the etiopathogenesis of several of the cholangiopathies (i.e., fibroinflammatory cholangiopathies and polycystic liver diseases), discuss their value as prognostic and diagnostic tools, and provide suggestions for further research.
胆管细胞是胆管树内衬的上皮细胞,仅占肝脏细胞总数的一小部分(3%-5%),但其分泌的胆汁量占每日胆汁总量的40%。此外,胆管细胞是影响胆道的多种肝脏疾病(即胆管病)的靶细胞;对于大多数此类病症,其病理机制尚不清楚。微小RNA(miRNA)是一类小的非编码RNA,可在转录后调节基因表达。因此,miRNA谱的改变是胆管病病理生物学中几种蛋白质失调的基础,并且有望作为诊断和预后工具,这并不奇怪。在此,作者综述了与miRNA在几种胆管病(即纤维炎性胆管病和多囊肝病)的病因发病机制中的作用相关的近期研究工作,讨论了它们作为预后和诊断工具的价值,并为进一步研究提供了建议。